The randomised, double-blind, placebo-controlled crossover study involved 16 healthy, physically active adults. Each participant received a single AG1 dose and placebo during visits separated by at least one week.

Researchers tracked plasma folate, calcium, zinc, vitamin C, biotin, nicotinamide, pyridoxine, riboflavin, thiamine and hesperidin for eight hours. Exposure was higher with AG1 for every measured analyte except pyridoxine, which showed only a trend.

For R&D, the methodological value is clear: interactions among nutrients, matrix and dosage form can be addressed using pharmacokinetic design, making a necessary condition for systemic activity measurable.

Plasma appearance does not equal improved nutritional status or health. The small sample, acute observation and healthy population prevent extrapolation to chronic use, deficiency, clinical outcomes or comparisons with other products.

Why it matters

The study shows that a complex matrix can be investigated through defined pharmacokinetic endpoints instead of relying only on the ingredient list.

Evidence limit

An acute, single-dose study in 16 healthy adults. It demonstrates plasma appearance of selected nutrients, not clinical benefit, correction of deficiency or superiority over other formulas.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.

Read the original source · Frontiers in Nutrition ↗